Kiniksa Pharmaceuticals
KNSA
77 hedge funds and large institutions have $274M invested in Kiniksa Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 9 closing their positions.
167% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 9
64% more capital invested
Capital invested by funds: $167M → $274M (+$107M)
24% more funds holding
Funds holding: 62 → 77 (+15)
8% more ownership
Funds ownership: 78.75% → 86.75% (+8%)
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$35.1M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$11.9M |
| 3 |
LPC
Lion Point Capital
New York
|
+$7.76M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.62M |
| 5 |
SCA
Spearhead Capital Advisors
Wellington,
Florida
|
+$4.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$15.8M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$7.8M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.29M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$3.71M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$3.29M |
KNSA Hedge Fund Activity: Q1 2020 in Review
77 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q1 2020, worth a combined $274M — up 64% from $167M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new KNSA positions and 9 closed out — a net gain of 15 holders — while 22 added to existing stakes and 23 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $35.1M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $15.8M.
- 77 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q1 2020, up from 62 in Q4 2019.
- Funds reported $274M of Kiniksa Pharmaceuticals stock for Q1 2020, up 64% quarter-over-quarter.
- 24 funds opened new Kiniksa Pharmaceuticals positions in Q1 2020 and 9 closed out, a net change of +15 holders.
- The largest Kiniksa Pharmaceuticals buyer in Q1 2020 was Consonance Capital Management, an estimated $35.1M added.
- The largest Kiniksa Pharmaceuticals seller in Q1 2020 was ArrowMark Colorado Holdings, an estimated $15.8M sold.
Based on aggregated 13F filings for Q1 2020.